抗焦虑抑郁药物改善伴焦虑抑郁的原发性面肌痉挛症状有效性的研究

发布时间：2018-08-15 12:29

【摘要】：目的探讨抗焦虑抑郁药物改善伴焦虑抑郁的原发性面肌痉挛(HFS)患者症状的有效性。方法将60例伴焦虑抑郁的HFS患者分为2组。实验组给予A型肉毒毒素(BTX-A)+艾司西酞普兰治疗,对照组给予BTX-A治疗,于治疗前、后行焦虑自评量表(SAS)及抑郁自评量表(SDS)测评。结果 2组经治疗后症状均改善,治疗1周、1个月时2组间治疗效果无统计学差异;2周、3个月时实验组改善更明显。治疗后实验组平均SAS、SDS标准分较对照组下降明显,对照组于治疗后1个月及3个月较治疗前有统计学差异(P0.05),实验组2周后较治疗前差异有统计学意义(P0.05),1个月后2组间存在统计学差异(P0.05),且实验组BTX-A有效期更长。结论焦虑、抑郁与病情呈正相关,为HFS的并发症,加用抗焦虑药物可使HFS治疗效果更佳。
[Abstract]:Objective to investigate the effect of antianxiety and depression drugs on symptoms of patients with primary hemifacial spasm (HFS) with anxiety and depression. Methods 60 HFS patients with anxiety and depression were divided into two groups. The experimental group was treated with botulinum toxin A (BTX-A) Escitalopram, the control group was treated with BTX-A. Before and after the treatment, the patients were assessed with (SAS) and (SDS). Results the symptoms of the two groups were improved after treatment. After 1 week treatment, there was no significant difference between the two groups at 1 month, and the improvement was more obvious in the experimental group at 3 months. After treatment, the average standard score of SASN SDS in the experimental group was significantly lower than that in the control group. There were significant differences in the control group 1 month and 3 months after treatment (P0.05), the experimental group 2 weeks after treatment than before treatment significant difference (P0.05), 1 month after the two groups there was statistical difference (P0.05), and the experimental group BTX-A validity is longer. Conclusion anxiety and depression have positive correlation with the state of the disease, which is a complication of HFS. The effect of HFS can be improved by adding antianxiety drugs.
【作者单位】：中南大学湘雅医院神经内科;
【分类号】：R745.12

【参考文献】